| Whole antibody|
| Humanized (from mouse)|
Romosozumab (AMG 785) is a humanized monoclonal antibody that targets sclerostin for the treatment of osteoporosis.
Romosozumab was originally discovered by Celltech (now owned by UCB). Celltech entered in a partnership with Amgen in 2002 for the product's development.